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The UK’s 100,000 Genomes Project: manifesting policymakers’ expectations 
 
ABSTRACT 
The UK’s 100,000 Genomes Project has the aim of sequencing 100,000 genomes 
from UK National Health Service (NHS) patients whilst concomitantly transforming 
clinical care such that whole genome sequencing becomes routine clinical practice in 
the UK. Policymakers claim that the project will revolutionize NHS care. We wished 
to explore the 100,000 Genomes Project, and in particular, the extent to which 
policymaker claims have helped or hindered the work of those associated with 
Genomics England - the company established by the Department of Health to deliver 
the project. We interviewed 20 individuals linked to, or working for Genomics 
England. Interviewees had double-edged views about the context within which they 
were working. On one hand, policymaker expectations attached to the venture were 
considered vacuous “genohype”; on the other they were considered the impetus 
needed for those trying to advance genomic research into clinical practice. Findings 
should be considered for future genomes projects.  
 
KEYWORDS 
Genomics; genome sequencing; genetics; expectations; genohype 
 
INTRODUCTION 
The United Kingdom’s (UK) 100,000 Genomes Project aims to sequence 100,000 
genomes from UK National Health Service (NHS) patients who have a rare disease, 
an infectious disease or cancer by 2017. Launched in 2012, its central goal is to 
implement genomics innovation/testing on a national scale such that it becomes 
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routine in NHS practice. Alongside this, it also has a research goal to provide data for 
scientific discovery, making it the first ever research-clinical hybrid project within a 
national health service.1 The project has been described by policymakers as 
“revolutionis[ing] [the] fight against cancer and help[ing] 100,000 NHS patients” 
(Gov.uk. 2012) with “the potential to transform the future of healthcare…” (NHS 
England 2014; our underline).  
 
Such hyped descriptions of genetic/genomic innovations are not new. Scholars report 
a general “genetic optimism frame” within media and political representations of such 
technologies, which is now commonly referred to as “genohpye” (Nelkin 1995, 
Petersen 2001, Nerlich, Dingwall, and Clarke 2002). Such hype has been shown to 
over-emphasize the benefits of genetics/genomics through “breakthrough narratives”, 
and under-represent the risks (Bubela and Caulfield 2004, Henderson and Kitzinger 
2007, Nerlich, Dingwall, and Clarke 2002). Some social scientists have argued that 
such reporting has led to broken promises and hopes for the public and patients, and a 
public mistrust of genetic innovation and science more generally (Fitzgerald 1998, 
Zurr and Catts 2005). Other social scientists - those exploring the sociology of 
expectations and those exploring related notions of promissory discourses - have 
shown how this hype is not simply a by-product of innovation, but rather constitutes 
the innovation process itself (van Lente 1993, Michael 2000, Fortun, 2001, 2005, 
2008, Brown and Michael 2003, Borup et al. 2006, Hilgartner, 2015). By envisaging 
futures in the present using breakthrough narratives and future expectations it creates 
                                                        
1 Other research-hybrid projects not on a national scale include, for example, the United States Geisinger 
health systems’ MyCode® genomics data system and biobank, and the United States Mayo Clinic’s Center 
for Individualized Medicine. The research-hybrid set-up is interesting in terms of novel conceptions of 
innovation pathways and is the subject of a forthcoming paper (Dheensa and Samuel). 
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a shared positive vision of the technology. This acts performatively by prompting 
alliance-building and securing funding. In essence, hype associated with biomedical 
technology acts as a currency of “promissory capital” to drive the genetic bio-
economy and generate funding opportunities (Fortun, 2001, 2005, 2008, Thompson 
2005, Petersen and Krisjansen 2015, Joyner, Paneth, and Ioannidis 2016). The 
performative effects of previous genohype could, in fact, be argued to have played a 
role in the launch of the UK’s 100,000 Genomes Project.  
 
The 100,000 Genomes Project has promised to transform the NHS by 2017. It has 
sufficient funding, and the Department of Health has specifically established an 
organization - Genomics England - to ensure its goals are achieved. We wanted to 
explore Genomics England, and in particular how policymakers’ expectations 
associated with the project have helped or hindered those trying to deliver the project 
into clinical practice – especially since clinical implementation projects are not 
always easy to implement “on the ground” (Rogers 2003, Peters et al. 2013, May and 
Finch 2009, Williams 2014, The National Academies of Sciences 2016, Manolio, 
Ward, and Ginsburg 2016, Day et al. 2016). We were not necessarily interested in the 
clinical implementation process itself, or providing a deep description of what was 
happening in clinical practice, but rather how the company set up to deliver the 
project, Genomics England, was functioning under the umbrella of policymakers’ 
expectations. 
 
Using an interview methodology, in 2016, we explored the views and experiences of 
20 individuals associated with, or working for Genomics England. We discovered 
interesting views within the group regarding the extent to which they felt helped or 
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hindered by the “genohyped” context within which they were operating and we 
discuss these. We believe these findings will be useful considerations for any future 
genomes projects within the UK or internationally. Before doing so we provide a 
detailed overview of the 100,000 Genomes Project. To date, the venture has been 
described in little detail in the literature.  
 
The 100,000 Genomes Project 
The venture’s launch  
Decades of promissory discourses surrounding genetics and genomics have situated 
this field at the heart of many political health/research discussions in the UK, as well 
as internationally. Added to this, ex-UK Prime Minister David Cameron’s personal 
journey of having lost a son to a genetic condition meant that the political climate in 
the UK was perhaps more open and willing to fund such promissory discourses into 
action.  Thus, in 2009, and as part of the long political drive to implement genomics 
into healthcare, the UK House of Lords Science and Technology Committee called 
for the development of a “strategic vision for genomic medicine in the UK”.2 In 
response, the Government established the Human Genomics Strategy Group designed 
to monitor advances in genomics and develop a vision for the discipline within the 
NHS. The Strategy’s 2012 report explained the various steps needed to streamline 
genomics within the NHS and as such laid the foundations of the 100,000 Genomes 
Project (Human Genomics Strategy Group 2012: 9). Soon after the publication of this 
report, the venture was launched with the advertised aim to sequence 100,000 
genomes of NHS patients, focusing on rare disease, cancer and infectious disease. Its 
central goal is to implement genomics innovation on a national scale such that it 
                                                        
2 http://www.publications.parliament.uk/pa/ld200809/ldselect/ldsctech/107/10711.htm 
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becomes routine in NHS practice, though it also has an additional research goal (i.e., 
it is an innovative clinical-research hybrid project). The project received over £200 
million in initial investment (Monitor Deloitte 2015).  
 
More than just whole genome sequencing 
Whilst the Genomes Project bore out of a desire to bring patient benefit, to improve 
NHS infrastructure, and to drive research in the genetics arena, it also has the aim of 
kick-starting the development of a UK genomics industry3. Thus, as with many 
biotechnologies, the project was “justified in terms of [its] potential to generate 
economic value” and exemplifies the “bioeconomy” at play (Petersen and Krisjansen 
2015: 30). Indeed, the venture can be directly viewed as the realization of the 
Government’s 2003 vision to lead the world in harnessing the potential of genetics in 
healthcare (Department of Health 2003), and as such is expected to create 
opportunities for the genomics industry (Monitor Deloitte 2015). These opportunities 
are anticipated to come from services related to the Genomes Project such as the 
sequencing of the DNA, the data analysis and the clinical interpretation. It is also 
foreseen that as the scale of genomes data grows, analysis and interpretation services 
will be in high demand, driving investment in areas such as analytics, data 
management and data storage. As the Office for Life Science’s Genomics in Industry 
report has noted, the UK currently contributes 10% to the £8 billion global genomics 
market and it is anticipated that the genomes venture will double this proportion. The 
project is therefore much more than a DNA sequencing project. Moreover, it is about 
implementing the sequencing and interpretation of genomics into the NHS not only to 
bring patient benefit, but also for this benefit to be realized in terms of economic and 
                                                        
3 https://www.genomicsengland.co.uk/about-genomics-england/ 
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industrial “bio-value” (Waldby 2002, Rose 2001, Petersen and Krisjansen 2015).  
 
The National Health Service 
Genomics England is the limited company wholly owned by the Department of 
Health tasked with carrying out the rare disease and cancer arm of the Genomes 
Project, though it is the UK’s National Health Service (NHS) which has been tasked 
with delivering the venture. As such, the NHS has been deemed responsible for 
recruiting and consenting patients to the project, capturing clinical information about 
patients to inform DNA sequence analysis, and collecting and handling patients’ 
DNA samples prior to analysis. The latter function includes the processing of DNA 
samples: DNA extraction; barcoding, handling, identification; transport and transfer 
of samples; and sample storage. In order to fulfil its mission, in 2014 NHS England 
announced the formation of 13 Genomics Medicine Centres (GMCs) throughout the 
UK. These centres, each constituted of a number of alliance hospitals and 
organizations, were selected because of their track-record of providing excellence in 
genomic services. Their aim is to bring transformational change to the infrastructure 
of genomic medicine care delivery by delivering an end-to-end genomic medicine 
pathway. In spite of this, at the time of writing this paper (beginning of 2017), 
Genomics England/NHS were behind in their recruitment, with just over 17,000 
genomes having been sequenced and far, far fewer sequences being analysed or 
results returned. Our findings in this paper provided some insight into the reasons 
behind this.  
 
Commercial and academic partners 
 7 
Whilst the NHS is tasked with the delivery of the genomic vision, Genomics England 
is responsible for procuring the sequencing capacity, the data architecture, and the 
necessary tools to securely store and interpret the 100,000 sequences and allow access 
for clinicians and researchers4.  To do this, Genomics England has formed a number 
of partnerships with a range of commercial and academic partners. For example, to 
sequence the DNA, Genomics England formed a partnership with the Wellcome 
Trust, The Wellcome Trust Sanger Institute and Illumina to create a Genomic 
Medicine Sequencing Centre in Hinxton5, near Cambridge, UK. In terms of data 
analysis and interpretation, Genomics England has established the Genomics England 
Clinical Interpretation Partnership (GeCIP) of more than 2,000 funders, researchers, 
trainees and clinicians from across the UK and the world. One of the main purposes 
of this partnership is, via carefully controlled access to the data, to allow those within 
the partnership to conduct beneficial and useful clinical research on the genomic data. 
This partnership also has the broader role in health professional education and 
training. As yet, the partnership is not up and running to its full potential, and it is still 
too early to tell whether this framework for analysis will be successful in the future. 
Genomics England has also established the Genomics Expert Network for Enterprises 
(GENE) Consortium - a selection of industry partners who are allowed access to 
Genomics England’s data during an industry trial throughout 2015. In this consortium 
Genomics England remains the owner of the genomic sequences (along with the 
consequent legal and ethical consequences of this) and members are expected to pool 
knowledge and share the results of their analysis6. However, again, little is known 
about the outcome of this trial or whether this approach to interaction with industry 
                                                        
4 https://quarterly.blog.gov.uk/2014/01/30/100000-genomes/ 
5 https://www.genomicsengland.co.uk/wp-content/uploads/2014/11/GeCIP-Guidance_FINAL.pdf 
6 https://www.genomicsengland.co.uk/clinicians-researchers-and-industry-collaborate-with-the-100000-
genomes-project/ 
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has been productive. Moreover, little is yet known about how the ethical issues 
associated with partnering with commercial entities might unfold. Though Genomics 
England does have an independent Ethics Advisory Committee to aid with ethical 
decision-making in relation to Genomics England’s policies and practice.  
 
METHODS  
Rationale 
As a medical ethicist and a medical sociologist working in the field of ethics, we were 
particularly interested in exploring how ethical issues associated with the Genomes 
Project have been, and are being, addressed by individuals on its Ethics Advisory 
Committee, as well as by those involved in the policymaking aspect of the initiative 
more broadly. We conducted 20 interviews with members of the Ethics Advisory 
Committee, the board of Genomics England, staff members, and those more broadly 
associated with the project to explore these issues. Some interesting insights emerged 
from our data with relation to how “ethics” was framed and performed within the 
organization. However, increasingly, during the course of our interviews, it was 
striking how much of the participants’ narratives revolved around the policymakers’ 
expectations of the project. It is these findings which are reported here. This is in line 
with the similar experiences of author 2, in which during a project exploring “new 
genetics” in ante-natal care, health care professionals were more interested in talking 
about issues relating to Down’s Syndrome.  
 
Recruitment 
Potential respondents were recruited in the summer of 2016, at the approximate half 
way mark through the 100,000 Genomes Project. Invites requesting participation in 
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the research study, including participant information sheets, were emailed to 
individuals associated with, or those who worked for Genomics England. Individuals 
from the following categories were invited: Genomics England staff members; 
Genomics England board members; Ethics Advisory Committee members; 
representatives from the Department of Health, Public Health England, NHS England, 
Genomics Medicine Centres (GMCs); and those involved in the evaluation of the 
100,000 Genomes Project. Board member Professor Mike Parker and Head of Ethics, 
Laura Riley, assisted with recruitment by providing the names and email addresses of 
relevant individuals. Individuals were requested to respond to the email invite if they 
were interested in participating in the research project, or if they had any questions. A 
maximum of two follow up emails were sent to non-responding individuals.  
 
Interviews 
20 individuals responded to the email invite and 20 semi-structured interviews were 
conducted. All of the categories of individuals listed in the above section were 
represented in the interviews (exact n numbers are not provided to protect 
confidentiality given the small-scale nature of the project). All participants signed a 
consent form prior to the interviews commencing. Interviews were conducted either 
by telephone or face-to-face (at a location chosen by the participant), lasted between 
30 and 105 minutes, and were audio-recorded. The interview schedule was broad, 
asking participants about their background and their role associated with the 100,000 
Genomes Project. Participants were also asked their views on the project; on its 
benefits (present and potential) and drawbacks; on any issues they had come across in 
relation to their role in the project and how these had been overcome; and on the 
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project’s political basis, as well as its ethics and public engagement strategy. 
Interviews were transcribed either by GS or by an external transcribing service.  
 
Analysis 
Analysis of interview data was approached using inductive reasoning employing the 
inductive approach of grounded theory (Strauss 1987, Charmaz 2006). The analysis 
(or coding) of data was based on two inter-linked rounds: overview analysis and 
detailed analysis (Strauss 1987). Overview analysis consisted of memo-making and 
broad coding. Extensive memo-making was employed by the interviewer directly 
after each interview. Broad coding proceeded by scanning the interview transcripts 
for relevant ideas and themes. Detailed analysis of the full transcripts occurred line-
by-line using NVivo software. Coding was carried out via constant comparison, 
which was continual, rigorous and allowed for developing and refining of conceptual 
categories as theory was developed. Due to the limited number of individuals 
associated with Genomics England, and the need to protect confidentiality, 
comparisons between respondents from different institutions are not reported.  
 
Ethics approval 
Ethics approval was granted by Brighton and Sussex Medical School Research 
Governance and Ethics Committee (RGEC). Reference 16/014/FAR. 
 
FINDINGS 
Interviewee’s narrated two accounts of policymakers’ expectations about the 100,000 
Genomes Project. One account pointed to a wide-range of issues which were 
hindering the project’s implementation into clinical practice as an illustration of why 
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policymakers’ aspirations to sequence 100,000 genomes by 2017 was overly 
optimistic. Their dialogues resonated with previous literature which we discussed 
earlier, that highlights the pitfalls of unfulfilled promissory “genohype” often 
associated with genetic/genomic innovation (Borup et al. 2006, Brown and Michael 
2003, Petersen and Krisjansen 2015). In the other contrasting account, interviewees’ 
perceived the expectations attached to the 100,000 Genomes Project as mobilizing an 
impetus in their attempts to overcome the wide-range of issues which were hindering 
the project’s clinical implementation. Below we explore these two accounts in detail. 
We note that the accounts of each interviewee could be situated within either 
narrative, somewhere in between, or as a mixture of both. We are careful not to 
identify participants in terms of their organisations, but note that there was some, 
though little, in the way of distinction between where interviewee’s accounts sat 
within or between these two different narratives and their respective host Institutions 
or job roles. 
 
Over optimistic expectations and genohype  
In our interviewees’ first account of the promises associated with the 100,000 
Genomes Project, the expectations of policymakers were viewed as “optimistic” 
(interviewee 4) and “overpromised” (interviewee 20). Interviewees pointed towards 
the as yet under performance of Genomics England in achieving its goals (roughly 
17% of genomes sequenced at time of interview, midway between the project). These 
feelings of over overpromise rested almost in their entirety on the short time scale 
with which the project needed to be completed. There was an awareness that whilst 
the relative ease with which genomes can be sequenced marked one of several spurs 
for the development of the project, sequencing 100,000 genomes was much more 
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complicated then the mere act of DNA sequencing. Sitting on one side of this was a 
complexity to “making sense of it [the sequence]”: “you can churn out 3 billion base 
pairs for $500 probably, but how much does it cost to make sense of it” (interviewee 
3). This was especially true given the dual research-clinical nature of this project and 
the fact that innovation was occurring alongside delivery – the technology to handle 
and interpret such a large genomic data set was being developed concomitant to the 
collection of samples. On the other side, and the side focused on within this paper, 
there was the necessity to recruit patients and collect samples. Here, interviewees 
explained that the expectations attached to the project were unrealistic because the 
delivery and implementation of the project was to be carried out by the NHS. As such, 
much of the success of the 100,000 Genomes Project was “dependent on hospitals” 
(interviewee 15), relying on them to recruit individuals and collect DNA samples. It 
was acknowledged that the promise of the genomes venture was entering an already 
socially organised environment (the NHS) with its own firmly embedded political 
interests, as well as organisational, social, professional and cultural norms (“there are 
lot of social and institutional and professional and cultural barriers in the way of it 
working” (interviewee 13)). Such norms involved differing expectations about 
genomics, the importance of the Genomes Project, and its associated aims. A 
realization existed that to achieve the transformational shifts within the time frames of 
the project, a change in the thinking of the NHS and its staff towards genomics, and 
specifically this project, was needed. Altering these norms and expectations to 
harbour the project was seen as one of the keys to the project’s success. This, 
however, was perceived as not easy, with interviewee 4 noting that “there is the 
problem about how you persuade clinicians to join in…[because]…it is very difficult 
to shift NHS clinicians to that [genomic England’s] position” (interviewee 4). Indeed, 
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speaking about organizational shifts post sequencing, interviewee 10, for example, 
noted that unanswered questions remained about how such a “transformational” 
(interviewee 9) change of the NHS could occur:  
 
Right from the start was…the knowledge that GEL [Genomics England Ltd] 
generated would inform clinical practice in the NHS, and that brings with it a 
number of organizational tensions …is the infrastructure of the NHS going to 
be capable of incorporating this knowledge? Will we have the ability to use it 
properly?...What’s the skill needs that we will need within the health service to 
be able to deliver genomic medicine quickly and equitably? So there are a 
huge number of issues that need to be resolved or need to be addressed for it 
to be successful 
 
Such tensions were viewed as especially pertinent by many interviewees given the 
“cash-strapped busy NHS” (interviewee 11): “when you actually put yourself down in 
the trust with its own costs and constraints, and many of the trusts are under special 
financial measures, that’s not their key priority” (interviewee 12).  
 
Interviewees’ accounts revolving around overpromise were therefore contextualized 
by the friction emerging between on the one hand those working at Genomics 
England needing to meet the grandiose expectations of the 100,000 Genomes Project 
set by policymakers, and on the other, the differing priorities, expectations, cultures, 
norms and organizational landscape of the NHS as a ground for clinical 
implementation of the project: “I don’t think we knew when we started …how complex 
it would be to build the infrastructure…you could say we may have been naïve” 
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(interviewee 4). Interviewees provided detailed examples to substantiate their views 
about policymakers’ unrealistic expectations and below we briefly note two such 
illustrative examples. 
 
Examples of the types of issues faced during clinical implementation 
The 100,000 Genomes Project requires that about 70,000 patients (100,000 
sequences) be recruited to the project via the NHS. However, as all interviewees 
noted, this has not been an easy task for the cancer arm of the study (“cancer has been 
difficult..[..]..in cancer they are struggling” (interviewee 10)) due to the differing 
priorities, expectations and culture of the NHS. For example, for interviewee 11, the 
research-clinical hybrid nature of the project meant that, rather than falling on an 
employed research nurse, recruitment responsibilities fell onto frontline clinical 
healthcare professionals – a staff team which was already “stressed” and “busy”, and 
maybe not very interested in assisting the genomes venture achieve its goals and 
fulfill its expectations: “if you go along and say well this patient’s in a research study 
and that they need an extra two blood samples taken in half an hour, can you do 
that..[..].. if you're in a stressed busy clinical environment; it’s easier to not ask the 
question…” (interviewee 11). Compounding this was the fact that many on this staff 
team may have little interest in research, or pursuing research endeavours: 
 
I don’t think it’s [research] is as embedded in the frontline NHS psyche as we 
like to think it is….some nurses think that research is just and add on and a 
faff and they don’t want to worry about it. So I think there’s a culture change 
to be done…[..]..it’s back to anything that makes things a bit different for 
them. They’ve got their routine, just processes that they do (interviewee 11) 
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For interviewee 18 a different concern about the differing priorities of the NHS versus 
the Genomes Project was apparent. This interviewee viewed a potential gap between 
executive support for the venture, and those individuals who are actually responsible 
for NHS day-to-day frontline recruitment. And, as this interviewee explained, for the 
latter, many clinical healthcare professionals may have personal and financial 
interests elsewhere, within their own already secured separate research funding. As 
such, recruitment for the project might be de-prioritized: “clinicians that work for the 
local trust and whose own research grants come from [other research funding 
bodies] are simply saying ‘right, I've got this person to agree to a clinical trial; let's 
not complicate the issue by throwing anything else in’” (interviewee 18). This was 
also of institutional concern, where the already high prevalence of clinical trials 
occurring within clinical cancer centres meant that vested interests remained here as 
opposed to the new genomics project in terms of removing samples from patients:  
 
A lot of the cancer trials currently going on require samples and there’s an 
issue about how big the samples need to be to satisfy both Genomics 
England’s requirement and Cancer Research UK's requirements. So I think 
there’s an argument there about just how much flesh you can cut out of one 
human being; [and also] the clinical trial requires tissue samples to be taken 
in this way and to be preserved in that way, that does not fit Genomics 
England’s needs, fine, they’re not going to look into it (interviewee 18) 
 
Beyond these issues with recruitment, for the Genomes Project to be successful once 
recruitment had occurred, DNA samples need to be collected from participants for 
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sequencing. However, similar to previous issues noted in the literature (Lazaridis et 
al. 2014), technical issues have emerged with the collection of cancer samples for 
genomic sequencing because the way in which tumour samples are routinely stored 
for processing damages DNA. Interviewee 16 explained that changing the sample 
processing protocol meant a huge organisational, professional, as well as cultural shift 
within the NHS: “what we had to do is to reengineer the way the National Health 
Service does this across its 13 Genomic Medicine Centres…” and as interviewee 7 
noted, this meant “developing new approaches to the handling of tissue, and as soon 
as you're saying you're going to do that, your reforming processes deep at the heart 
of pathology across the NHS” (interviewee 7). Interviewee 17 advised that whilst 
such changes may not seem like “rocket science”, they are often the hardest to 
implement in practice because of differences in priorities and expectations within an 
already stretched NHS.  
 
It’s not rocket science. It involves…steps like having someone on hand to 
carry the sample from the theatre to the path lab. Now, an actually busy 
hospital, just organizing that is not immediately obvious…it then can’t take 
two or three days to get to the path lab. It has to actually go there in a few 
hours…so all of that is in an NHS which is under pressure for all sorts of 
reasons, is not an easy thing to do…  
 
This change was perceived as particularly difficult and interviewee 4 was becoming 
increasingly frustrated that the NHS laboratories, who maybe did not share the vision 
of policymakers’ expectations about the Genomes Project, were opposing change to 
their “outdated model” of pathology testing: “I think that someone needs to take 
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people that run genomics labs in the NHS by the scruff of their necks and shake them 
up to the fact that….power comes from having high quality data that you use and that 
they are trying to keep to an outmoded model”. 
 
Overall then, the instances described above, and similar issues (including, but not 
limited the lack of resources and staff within the NHS to accommodate the 
transformation change, and the lack of education and support and to want to drive the 
change), were used by interviewees as illustrative exemplifiers of the overly 
optimistic expectations associated with the Genomes Project that it could fulfill its 
promises, and of the “underestimated” time (interviewee 9) provided with which to 
achieve said aims. Most of these instances can be tied together by the realization of a 
tension between the need for Genomics England to implement its aims, and the fact 
that the NHS as an oganizational structure did not, and more importantly could not, 
always share the same vision of genomics. Indeed, the “cash-strapped” NHS had/has 
its own set of issues to face on a day-to-day basis far removed from the 
implementation of genomics. And interviewee 5 noted that whilst the project was not 
“misconceived, [it was] rather simplistically assumed how easy it would be”. 
Interviewee 12 stated that “a very bold statement [the 100,000 Genomes Project 
announcement], but in terms of delivery, it just makes it impossible to do”.  
 
Expectations and the mobilization of motivation   
Interviewees also had an alterative account to the above perspective on policymakers’ 
expectations of the Genomes Project. From this second perspective, interviewees 
viewed the hype surrounding the venture as a mobiliser of the project. In this narrative 
the project’s political foundations were seen to bring benefits: “the most difficult thing 
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is that we are a political project, but that’s also the biggest advantage” (interviewee 
2). This was because the time pressure, borne out of the need to meet the expectations 
attached to the project meant that “[the project] wouldn’t have happened probably as 
quickly without that policy support” (interviewee 11); “we are where we are and a lot 
quicker than we would have been” (interviewee 17). And whilst the fast-pace of the 
project meant that it was “all a bit of a learning process” (interviewee 9), with very 
little time to plan ahead (“we are building the airplane while we are flying it” 
(interviewee 15)) so that some mistakes were being made (‘you make mistakes” 
(interviewee 17)), at the same time, it had its benefits. The speed was seen as “one of 
the ways to innovate really rapidly” (interviewee 16), and allowed years of “painful” 
planning to be avoided: “you ended up in these scenarios where people were trying to 
plan for every possible circumstance and it was incredibly painful and it was still 
chaotic at the end” (interviewee 2). As such, the political nature of the project, 
although causing friction, provided a “can-do attitude” (interviewee 1), and was 
“needed” to force paced decision-making: “I think the friction that has happened, the 
pace of things, I think that needed to happen because academics would always - they 
would take far too long to come to this decision” (interviewee 18). Interviewee 2, for 
example, spoke about the political rhetoric giving the project “impetus” to drive 
change: “the fact that we are a political project with a political view means that we 
have that focus to be concentrated on driving a lot of the change…there is a lot of 
political rhetoric around it because that’s what’s given it the impetus” (interviewee 
2).  
 
In this account of policymakers’ promises, interviewees perceived the project’s tightly 
framed expectations and deadlines as working positively to help surmount the issues 
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facing the project’s clinical implementation described above. This was because the 
speed with which the Genomes Project needed to work to meet such expectations was 
viewed as the necessary factor to drive change in NHS culture: “if you go to slowly 
you end up with compromise of the lowest common denominator. The objective was 
absolutely to drive this fast, to have the NHS and our researchers ahead…and not to 
give people time to downgrade it” (interviewee 4). As interviewee 17 remarked, the 
idea was that if the project - which needs to overhaul NHS services - moves fast 
enough, the NHS would not have time to “work out its defence” to any 
organizational, cultural, social and professional changes required within the NHS, 
thus making any transformations easier: 
 
If you’re not careful, you get caught up in normal human defence to change. If 
you move fast enough, you can, to a degree, minimize that [laugh]…I’m told 
by people who've been in the business much longer than I have that all 
previous attempts to reform pathology have failed. But we seem to be getting 
there. I think that’s possibly because we’ve arrived at such speed…we had to 
change before the system worked out its defence to that (interviewee 17) 
 
Therefore, whilst the project did raise a range of clinical implementation issues, the 
alternative i.e., not implementing the project with the policymakers expectations 
attached, was not viewed as necessarily any better: “change is always painful 
[and]…I recognize the challenges [of having the political expectations tied into the 
project], but when people talk about alternatives, I think that they are perhaps being 
a little naïve in thinking that those alternatives would necessarily be better” 
(interviewee 2). In fact, whilst the nature of the expectations meant that it was 
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“uncomfortable” and “tough” for the workforce whom were trying to implement the 
Genomes Project, it was the tight deadlined expectations themselves which, in 
essence, provided the motivation and momentum that was needed as they attempted to 
drive a cultural shift in priorities within the NHS: 
 
I think it’s very uncomfortable for everybody…but I think it’s a very brave 
project and it is one way to get the NHS to change systems is just to say it’s 
changing and see how everybody innovates and how everybody works around 
that and I think that is the policy, that is the motivation.  So I probably think 
it’s a good thing, a good thing for patients eventually... (interviewee 9) 
 
This is not to say whether or not this expectation-driven motivation would lead to the 
project’s success, since we have no way of knowing this from this data, but rather 
there was a view that the policymakers’ expectations mobilized an “impetus” and 
motivation for individuals within Genomics England in their attempts to drive the 
project forward.  
 
It is worth noting that having one entrepreneurial company - Genomics England, both 
responsible and answerable for meeting the expectations for the project’s eventual 
success most likely facilitated the momentum/motivational affects of the 
policymakers’ expectations. Having this focal point meant that the impetus and drive 
could abound throughout the company, its staff and associated individuals. These 
could then be championed outside of the project more broadly (Lazaridis et al. 2014, 
Kukk, Moors, and Hekkert 2016). Indeed, interviewee 3 felt that the status of 
Genomics England as an entrepreneurial company meant that in the face of tight 
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deadlines and expectations, it was more likely than academics/scientists to adopt a 
can-do attitude in the face of trying to change NHS clinical culture: “it’s very difficult 
to get the [translational] stuff into the clinic, and I think part of the problem is science 
itself and scientists. They are not brave enough..[..]..the entrepreneur [Genomics 
England]…will take a judgment…and then will do something about it”.  
 
CONCLUDING REMARKS 
This paper has explored how policymakers’ expectations manifested within the UK’s 
recent and ongoing 100,000 Genomes Project. Our interviewees’ narrated two 
accounts relating to this. The first emphasized the various understandable issues 
hindering the project’s implementation into clinical practice as an illustration of what 
interviewees viewed as the overly optimistic “genohype” associated with the project. 
In constructing this narrative, interviewees’ accounts reflected what is already known 
about the complex process of implementation (May and Finch 2009) and thus viewed 
the grandiose statements and promises affixed to the Genomes venture as “naïve” and 
“overpromised”. The second account perceived the expectations of the project, 
particularly given the time constraints attached to them, as acting as an impetus and 
motivator of Genomics England’s efforts to drive clinical implementation and 
delivery. This can be compared to previous work exploring the future-orientated 
expectations attached to other biomedical innovations/other genetic/genomic 
technologies, which have been shown to do performative work in the generation of 
funding, the promotion of alliance building and the allocation of resources (Hedgecoe 
and Martin 2003). Only here, in a company which has been already fully funded, the 
expectations are functioning as a stimulus for individuals within Genomics England, 
working to drive change.  
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The presence of these two different accounts of the 100,000 Genomes Projects’ 
political expectations immediately suggests a possible relevance of the work of 
Gilbert and Mulkay. These authors have drawn on extensive research in the field of 
biochemistry, and in particular oxidative phosphorylation, to argue that scientists’ 
descriptions of their actions and beliefs about science are context-specific. The 
authors note two predominant styles of interpretation of events: those in the formal 
context, based on an empiricist repertoire (i.e., often seen in academic journals - 
science as impartial; scientists are detached) and those in the informal context, based 
on a contingent repertoire (i.e., drawing on social, psychological and other factors), 
often used to explain away controversies or “others’” errors in science. Such 
discourses, say the authors, are reconciled by the belief that social distorting 
influences which cause errors and controversies in science will eventually be made 
apparent and science will prevail (Gilbert & Mulkay, 1984). The authors argue that 
both discourses are equally important and valid, and rather than trying to combine 
them to form one interpretation of events (as is typically the case), they recommend 
different participants’ discourses be treated as a topic of analysis as a whole made up 
of different but not necessarily inconsistent parts.  
 
Applied to our findings, this would suggest that interviewees’ discussions promoting 
the benefits of the political expectations attached to the Genomes Project reflect the 
formal, empiricist repertoire or version of events; whereas interviewees’ discussions 
about the difficulties faced by the project are contingent – interviewees maintain their 
own credibility and that of Genomics England by explaining away difficulties using 
“genohype” and other social/organizational issues such as those related to the need to 
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rely on the NHS. This is an interesting way to consider our findings, and sits 
alongside the approach we have taken. 
 
Moving beyond a discourse approach, some of our findings are not unexpected. 
Interviewees accounts of overpromise and issues with clinical implementation are 
unsurprising given that those who are involved in the project are likely to want to 
explain how hard the project has been, and express concern about being able to 
deliver the project – especially given the issue of resources within the NHS, a point 
further explored by Day and colleagues in their ethnographic study of a large, 
research intensive NHS breast cancer service implementing a stratified medicine 
approach (Day et al. 2016). More surprising were interviewees’ perspectives on the 
benefits of working under difficult time constraints - constraints which were also 
viewed as overpromised. One might expect that interviewees would only have 
negative things to say about working under these conditions (and a lot of them did 
indeed express the pressure which had been placed on the workforce). Yet this was 
not always the case, benefits were also noted. Talking to individuals at Genomics 
England suggested that when trying to make a big (national) shift from research to the 
clinic, working to tight deadlines, and working within a pressured environment, whilst 
“tough” and “uncomfortable”, was having a motivational role. This was seen as then 
acting to provide the momentum required by Genomics England in its attempts to 
drive change in clinical practice – a practice which is well-known to be particularly 
resistant to such change and a phenomenon sometimes referred to as clinical inertia. 
This is not to say that the impetus and motivation generated from policymakers’ 
expectations will indeed bring about the project’s success - we have no way of 
knowing if the project will be successful from this data, and indeed (whilst not 
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genome sequencing), Day and colleague’s ethnographic study suggests a whole range 
of issues affecting patient care during the implementation of a stratified medicine 
approach (Day et al. 2016). Rather, with well-acknowledged time constraints hanging 
over Genomics England, the expectations attached to the Genomes Project 
inadvertently acted as a currency of hype (Petersen and Krisjansen 2015) – a vision of 
what needed to be achieved. This then provided a stimulus, a perceived necessary 
factor, as Genomics England attempted to drive clinical change. This can be 
compared to other ‘currencies of hype’ and promissory discourses disseminated by 
companies within the field of genomics, for example those associated with the 
synthetic biology ‘Biobricks group’, explored by Hilgartner (Hilgartner, 2015), and 
those associated with deCODE Genetics - explored by Fortun (Fortun, 2001). In the 
latter case, Fortun argued that the promises, hype and ‘stories’ promoted by deCODE 
genomics were integral to the science and business of the company, and that ‘to the 
extent that we can say it is ‘based’ on anything, the genomics industry is based 
on…what genetic information may become in the anticipated, contingent future…. 
there can be no economy without hype...’ (Fortun, 2001: 145-6). Whilst our findings 
suggest a positive role for the presence of such hype and promissory discourses, 
Fortun in comparison, comments that ‘six years of researching, speaking on, and 
writing about deCODE…here is a case so chock-full of false and broken 
promises…that I can confidently make the ‘forward-looking statement’ that Kari 
Stefansson [CEO and founder of deCODE] has the least right to make promises of 
any genomics company CEO I know’ (Fortun, 2005: 158). Happily the researchers in 
this instance were not compelled to reach a similar conclusion. 
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To summarize, then, these findings caution us not to view the genohype surrounding 
the venture as just vacuous hype, something which is hindering the project, or is 
problematic because it over promises what cannot be delivered. Whilst the project 
may have been “overpromised” and “misconceived” (it is too early to tell), the 
promissory discourses attached to it have become a part and a drive of the project 
itself. Having an entrepreneurial Genomics England with full responsibility for 
achieving the project’s promised political goals as a focus for this drive and 
motivation; and having a specific time frame with which Genomics England needs to 
meet these expectations; has allowed the project to acquire momentum as Genomics 
England uses all its effort to enact change at the level of clinical delivery. Thus, whist 
expectations and promissory discourses can lead to negative outcomes (as noted in 
relation to Fortun’s analysis of deCODE above (Fortun, 2005)), it is important to 
recognize that this is not always the case. These findings should be considered during 
the development of any future genomes projects within the UK, and also 
internationally. 
 
By way of limitations, we note that our interviewees were self-selecting individuals 
approached through a contact list provided by Genomics England. This self-selection 
of participants may have created a particular bias, and there may have been others at 
the company who would have provided valuable insight who did not participate in the 
study. Furthermore, the interviews were conducted in 2016, before the 100,000 
Genomes Project’s completion. As we have noted above, further research needs to be 
conducted to explore how the innovation process progresses; whether (and/or how) 
successful clinical delivery is implemented; and whether the promissory discourses 
associated with the initiative lead to real benefits, or whether these “communities of 
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promise” - or “genohype” - fall apart and migrate to new areas, as described in the 
“sociology of expectations” (Michael 2000, Brown and Michael 2003, Borup et al. 
2006).  
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